CSTL — Castle Biosciences, Inc.

Castle Biosciences (CSTL) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $83 million for Q3 2025, a significant increase from $80.7 million in Q3 2024.
• Test Report Volume: 26,841 reports, a 36% increase year-over-year.
• DecisionDx-Melanoma Reports: 10,459, marking a 12% year-over-year increase and surpassing 10,000 reports in a single quarter for the first time.
• DecisionDx-SCC Reports: 4,186 reports, maintaining high volume without proactive marketing.
• Gross Margin: 74.7%, down from 79.2% in Q3 2024; adjusted gross margin was 76.8%, down from 81.9%.
• Net Loss: $0.5 million, compared to a net income of $2.3 million in Q3 2024; diluted loss per share was $0.02.
• Adjusted EBITDA: $9.2 million, down from $21.6 million in the same quarter last year.
• Cash Position: $287.5 million in cash, cash equivalents, and marketable securities.

2. Strategic Updates and Business Highlights

• Launch of AdvanceAD-Tx: A new test for guiding systemic treatment selection for moderate to severe atopic dermatitis, targeting a $33 billion market.
• Clinical Validation: AdvanceAD-Tx demonstrated the ability to identify patients likely to respond to JAK inhibitors versus Th2-targeted therapies.
• DecisionDx-SCC Updates: New peer-reviewed evidence supports its clinical utility, enhancing its role in managing high-risk squamous cell carcinoma.
• TissueCypher Growth: Achieved 10,609 test reports, a 75% year-over-year increase, indicating rising recognition among clinicians.
• Reimbursement Efforts: Ongoing efforts to secure reimbursement for AdvanceAD-Tx, with expectations of immaterial revenue contribution in 2026.

3. Forward Guidance and Outlook

• Revenue Guidance: Increased for 2025 to a range of $327 million to $335 million, up from $310 million to $320 million.
• DecisionDx-Melanoma Volume Growth: Expected to maintain high single-digit growth for the full year 2025.
• SCC Test Revenue: Anticipated to be modest, with a conservative outlook on future contributions.

4. Bad News, Challenges, or Points of Concern

• Declining Gross Margin: Notable decrease in gross margin metrics, raising concerns about cost management amidst rising expenses.
• Net Loss: Transition from profitability to a net loss compared to the previous year, indicating potential operational challenges.
• SCC Test Reimbursement Uncertainty: Ongoing uncertainty regarding Medicare coverage decisions and the impact on SCC test utilization.
• Market Penetration Risks: While there is significant potential for growth, the company faces challenges in expanding physician adoption and navigating reimbursement landscapes.

5. Notable Q&A Insights

• Market Addressability for AdvanceAD-Tx: Approximately 13.2 million patients with moderate to severe atopic dermatitis, with an estimated 10-20% being Medicare age.
• Reimbursement Pathways: Discussions around multiple reimbursement avenues, including commercial payers and Medicare contractors like Novitas and MolDx.
• SCC Volume Stability: Despite flat quarter-over-quarter volumes, management expressed confidence in the clinical value of the SCC test.
• Sales Force Impact: Refocusing the dermatology sales team has contributed to growth in DecisionDx-Melanoma, with both new and existing clinicians driving volume increases.
• FDA Approval Discussion: Pursuing FDA approval for DecisionDx-Melanoma, though management does not expect immediate changes to Medicare rates as a result.

This summary encapsulates the key points from Castle Biosciences' Q3 2025 earnings call, highlighting both achievements and challenges as the company navigates its growth trajectory in the dermatology testing market.